Bharat Parenterals is planning to acquire additional 99,85,477 equity shares having Face value Rs 10 per share with a premium of Rs 54.90 per share aggregating of Rs 64.90 per share of Innoxel Lifesciences, a Subsidiary company of the company on a preferential basis. The Investment is made for expansion of existing plant and working capital requirement of the Subsidiary Company. The said acquisition is expected to be completed by June 30, 2024 subject to approval of shareholders.
Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.
